Europe Pen Needle Market Research Report Information By Product (Standard Pen Needle, And Safety Pen Needle), By Needle Length (4MM,5MM,6MM,8MM,10MM, and 12.7MM), By Application (Insulin Therapy, Glp-1 Therapy, Growth Hormone Therapy, Osteoporosis, And Others), By Distribution Channel (Direct Sales, And Distributors), And By End User (Hospitals & Clinics, Homecare Settings, And Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Europe Pen Needle Market Overview

Europe Pen Needle Market size was valued at USD 0.75 billion in 2022. The Europe Pen Needle Market industry is projected to grow from USD 0.82 billion in 2023 to USD 1.88 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.61% during the forecast period (2023 - 2032).

The factors contributing to the growth of the market are the increasing prevalence of diabetes, obesity, and various chronic diseases, rising awareness of self-administration of injectable medications, and patient's preference for pen devices.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Pen Needle Market Trends

•  INCREASING PREVALENCE OF DIABETES, OBESITY, AND OTHER CHRONIC DISEASES

The Europe pen needle market has witnessed significant expansion, primarily fueled by the escalating prevalence of diabetes, obesity, and various chronic diseases. According to the World Health Organisation (WHO) in 2023, there were approximately 60 million diabetics in the European Region, accounting for 10.3% of men and 9.6% of women aged 25 and up. Furthermore, diabetes is becoming more common in people of all ages across Europe, owing primarily to increases in overweight and obesity, an unhealthy diet, and physical inactivity. The relentless rise in diabetes cases, coupled with the parallel increase in obesity rates—an established risk factor for diabetes—has substantially propelled the demand for efficient and patient-friendly insulin delivery devices, including pen needles. This surge in demand is a direct response to the growing need for accessible and effective self-administration of injectable medications. As chronic diseases become more pervasive on a Europe scale, there is an increasing reliance on advanced medical solutions to meet the evolving healthcare challenges. The aging population, coupled with shifting lifestyle patterns, has contributed to a higher incidence of these conditions, creating a sustained demand for innovative medical technologies. Concurrently, ongoing advancements in pen needle technology, focusing on aspects like pain reduction, user-friendly features, and enhanced patient adherence, are pivotal contributors to the market's growth trajectory.

The Europe pen needle market has experienced notable expansion, driven significantly by the rising awareness of self-administration of injectable medications. As patients increasingly recognize the benefits of managing their treatment independently, the demand for user-friendly insulin delivery devices, such as pen needles, has seen a considerable upswing. The emphasis on empowering individuals to take control of their healthcare, particularly in the context of chronic conditions like diabetes, has spurred a preference for convenient and accessible solutions. The awareness campaigns and educational initiatives promoting the advantages of self-administration have played a pivotal role in shaping consumer behavior.

Therefore, rising incidences of vaginal dryness, the growing geriatric population, and the increasing availability of products are fueling market growth.

Europe Pen Needle Market Segment Insights

Europe Pen Needle Product Insights

Based on the product, the Europe pen needles market has been bifurcated into standard pen needle and safety pen needle. The standard pen needle segment held the largest market in 2022 and is the fastest growing segment during the forecast period.

Europe Pen Needle Length Insights

Based on needle length, the Europe pen needle market has been segmented into 4mm, 5mm, 6mm, 8mm, 10mm and 12.7mm. The 4mm segment held the largest market in 2022 and is the fastest growing segment during the forecast period.

Europe Pen Needle Application Insights

Based on application, the Europe pen needle market has been segmented into insulin therapy, GLP-1 therapy, growth hormone therapy, osteoporosis, and others. The insulin therapy segment held the largest market in 2022 and is the fastest growing segment during the forecast period.

Europe Pen Needle Distribution Channel Insights

Based on the distribution channel, the Europe pen needle market has been segmented into direct sales and distributors. The distributors segment held the largest market in 2022 and is the fastest growing segment during the forecast period.

Europe Pen Needle End User Insights

Based on end user, the Europe pen needle market has been segmented into hospitals & clinics, homecare settings, and others. The homecare settings segment held the largest market in 2022 and is the fastest growing segment during the forecast period.

FIGURE 2: EUROPE PEN NEEDLE MARKET, BY END USER, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Pen Needle Regional Insights

By region, The Europe pen needles market is segmented into the France and Rest of Europe. The Rest of Europe held the largest market share and is anticipated to dominate the overall needle pen market during the forecast period. Europe spearheaded the lancet and pen needles market in 2019 and is likely to continue to command during the assessment period. This can be attributed to the rising prevalence of infectious diseases, new product approvals, and the presence of developed healthcare infrastructure in most European countries. The growing prevalence of the diabetic population and the need for diabetes diagnosis are the key market driving factors. According to the International Diabetes Federation, in 2021, 61 million were diagnosed with diabetes in Europe. Also, Europe has the highest number of children and adolescents with type 1 diabetes which accounts to be 295,000. Out of which 3,942.9 per 1000 patients with diabetes are from France. Thus, the factors mentioned above facilitate the growth of the lancet and pen needles market in Europe during the forecast period.

Further, the major countries studied are France and the Rest of Europe.

FIGURE 3: EUROPE PEN NEEDLE MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Pen Needle Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their products, which will help the Pen Needle Market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Pen Needle industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Novo Nordisk A/S (Novo Nordisk) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. It has R&D facilities in the US, Denmark, India, China, and the UK. Drugs for obesity, atherosclerosis, hemophilia, Type 1 and Type 2 diabetes, and growth abnormalities are well-served by its robust clinical pipeline. It also offers pre-filled insulin delivery systems, glucagon hypokits, insulin, recombinant hemophilia drugs, cartridges, needles, vials, and oral antidiabetic pharmaceuticals. The company sells its products through companies located in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia. The company operates in 79 countries and markets its products in more than 170 countries.

Key Companies in the Europe Pen Needle Market includes.

• Novo Nordisk A/S


• Terumo Corporation


• Nipro Europe Group Companies


• Shanghai Beipu Medical Co., LTD.


• Promisemed Medical Devices Inc.


• TaeChang Industrial Co., Ltd.


• Vitrex Medical A/S


• Embecta Corp.


• Ypsomed Holding AG


• MTD Medical Technology and Devices


• Others

In December 2021, Owen Mumford (UK) launched a home-use pen needle, namely the Unifine Ultra, the world's most extraordinary. Unifine Ultra is a one-of-a-kind home-use pen needle that is intended to provide the ultimate solution for improving patient compliance and the injection experience. This product launch has expanded its reach across Europe and also assisted in generating revenue.

In September 2020, MTD Medical Technology and Devices' (Italy) brand manufacturer, HTL-STREFA, launched Droplet Micron, an innovative pen needle designed to deliver the best injection. Droplet micron is thinner and [m1] shorter than other pen needles available on the market, and hence, we have expanded our pen needle product portfolio with this innovative product.

Europe Pen Needle Market Segmentation

Europe Pen Needle Product Outlook